Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Medications › omecamtiv mecarbil

omecamtiv mecarbil

2 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials of omecamtiv mecarbil

3 trials tracked of omecamtiv mecarbil: 2 in phase 3 or 4 and 2 with published results. The most-cited published study has 61 citations.

3Trials tracked
2Phase 3 & 4
0Recruiting
2With published results
Phase distribution
Phase 3 2 Phase 1 1
  1. Phase 3 Study to Assess the Effect of Omecamtiv Mecarbil on Exercise Capacity in Subjects With Heart Failure Completed · 61 cited
  2. Phase 3 Registrational Study With Omecamtiv Mecarbil (AMG 423) to Treat Chronic Heart Failure With Reduced Ejection Fraction Completed · 5 cited
  3. Phase 1 Pharmacokinetics and Safety Study of Omecamtiv Mecarbil in Healthy Japanese Adults Completed

Showing the 3 most-cited and recently-updated of 3 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Higher LDH levels linked to increased heart failure events in HFrEF patients
Cardiology RCT
Higher LDH levels linked to increased heart failure events in HFrEF patients A Simple Blood Test Could Predict Heart Failure Worsening
This analysis of the Phase 3 GALACTIC-HF trial examined lactate dehydrogenase (LDH) levels in 8,179 patients with heart failure with reduced…
A widely available blood test for cell damage may help doctors spot which heart failure patients face the highest risk of hospitalization or…
May 7, 2026
Omecamtiv mecarbil shows trend toward reduced serious arrhythmia risk in HFrEF post hoc analysis
Cardiology RCT
Omecamtiv mecarbil shows trend toward reduced serious arrhythmia risk in HFrEF post hoc analysis Heart Drug Shows Promise Against Deadly Heart Rhythms
This post hoc analysis of a randomized controlled trial evaluated omecamtiv mecarbil versus placebo in 8232 participants with symptomatic ch…
A heart failure medication already shown to improve pumping strength may also protect against sudden cardiac arrest, especially in patients …
May 3, 2026